Health Canada Issues SOR/2025-248: A New Shortage Framework for Foods for a Special Dietary Purpose 

Health Canada Issues SOR/2025-248: A New Shortage Framework for Foods for a Special Dietary Purpose 

On December 17, 2025, Health Canada published SOR/2025-248, Exemption Order in Respect of Foods for a Special Dietary Purpose in the Canada Gazette, Part II. This Order creates a formal mechanism to help maintain access to medically important nutrition products when Canada faces a shortage or risk of shortage. It also supports continued market access for…
Read More
Health Canada Permits Caffeine in Supplemented Candies and Updates Labelling Requirements 

Health Canada Permits Caffeine in Supplemented Candies and Updates Labelling Requirements 

On November 25, 2025, Health Canada published a Notice of Modification updating the List of Permitted Supplemental Ingredients to expand the permitted use of caffeine and introduce a new mandatory cautionary statement for certain high-caffeine solid supplemented foods.  If you manufacture, import, or private label functional gummies, caffeinated candies, or other solid…
Read More
Health Canada Proposes Changes to Medical Device Establishment Licensing (MDEL): What Importers, Distributors, and Manufacturers Need to Know 

Health Canada Proposes Changes to Medical Device Establishment Licensing (MDEL): What Importers, Distributors, and Manufacturers Need to Know 

On November 8, 2025, Health Canada published proposed amendments to the medical device establishment licensing framework in the Canada Gazette, Part I. The consultation is open for stakeholder feedback until January 17, 2026. If you hold, or are planning to apply for, a Medical Device Establishment Licence (MDEL), these proposed changes…
Read More
Health Canada’s 2026 Proposed Updates to the Cosmetic Ingredient Hotlist: What Cosmetic Brands Need to Know 

Health Canada’s 2026 Proposed Updates to the Cosmetic Ingredient Hotlist: What Cosmetic Brands Need to Know 

Health Canada has begun a new consultation on proposed revisions to the Cosmetic Ingredient Hotlist, opening the door to significant changes in how cosmetic ingredients are reviewed, classified, and permitted for use in Canada. The consultation period runs from November 19th, 2025, to February 17th, 2026, marking a critical window for industry to…
Read More
Health Canada Proposes New Food Enzyme Authorization: Exo-inulinase 

Health Canada Proposes New Food Enzyme Authorization: Exo-inulinase 

On November 20th, 2025, Health Canada released a new proposal signalling its intention to authorize exo-inulinase from Trichoderma reesei strain AR 577 as a permitted food enzyme in Canada. If the proposal moves forward, the change would be implemented through an update to the List of Permitted Food Enzymes following a public consultation period that closes on February 3rd, 2026.  The List of…
Read More
2025 GMP Overhaul for Natural Health Products (NHPs): What It Means for Canadian Importers and Site Licence Holders

2025 GMP Overhaul for Natural Health Products (NHPs): What It Means for Canadian Importers and Site Licence Holders

When Health Canada released Version 4.0 of the Good manufacturing practices guide for natural health products (GUI-0158) on September 4, 2025, it marked the first major revision of good manufacturing practices (GMP) expectations in a decade. The new guide, which will become enforceable on March 4, 2026, following a six-month…
Read More
Understanding MDSAP and Its Role in Canadian Market Access

Understanding MDSAP and Its Role in Canadian Market Access

The Medical Device Single Audit Program (MDSAP), developed by the International Medical Device Regulators Forum (IMDRF), is a harmonized audit framework that allows a single ISO 13485:2016 audit, conducted by an approved Auditing Organization (AO), to meet the quality management system (QMS) requirements of multiple regulatory authorities simultaneously.  In Canada, MDSAP serves as the recognized mechanism…
Read More
Health Canada to Implement ICH E6(R3): What It Means and How to Prepare 

Health Canada to Implement ICH E6(R3): What It Means and How to Prepare 

On October 17th, Health Canada has confirmed it will implement the ICH E6(R3) Good Clinical Practice (GCP) guideline, a major international update to the way clinical trials are designed, managed, and documented. The goal is to strengthen participant safety, improve data quality, and modernize how clinical research is conducted in Canada. …
Read More
Cosmetic Labelling in Canada: What You Need to Know 

Cosmetic Labelling in Canada: What You Need to Know 

When introducing a new cosmetic product to the Canadian market, manufacturers and importers must meet several key regulatory obligations. Products must contain only safe ingredients that are permitted for cosmetic use, be properly notified to Health Canada through a Cosmetic Notification Form (CNF), and display labels that fully comply with…
Read More
NHP Clinical Trials – Feasibility and Portfolio Assessment

NHP Clinical Trials – Feasibility and Portfolio Assessment

Clinical trials for natural health products (NHPs) such as vitamins, herbal remedies, and probiotics bring scientific rigour to traditional health claims. In Canada, where consumer protection and evidence-based regulation are priorities, sponsors are beginning to shift away from running isolated trials toward building comprehensive clinical research strategies. This shift reflects…
Read More